Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences, Tokyo, Japan.
Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences, Tokyo, Japan; Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA.
J Infect Chemother. 2022 Oct;28(10):1393-1401. doi: 10.1016/j.jiac.2022.06.013. Epub 2022 Jun 29.
Little information is available on the temporal trends in the clinical epidemiology and in-hospital mortality of patients with coronavirus disease 2019 (COVID-19) in Japan for waves 1, 2, and 3.
A national claims database was used to analyze the time trends in admission, medical procedure, and in-hospital mortality characteristics among patients with COVID-19. Patients who were ≥18 years and discharged from January 1, 2020 to February 28, 2021 were included.
A multilevel logistic regression analysis of 51,252 patients revealed a decline in mortality in waves 2 and 3 (risk-adjusted mortality range = 2.17-4.07%; relative risk reduction = 23-59%; reference month of April 2020 = 5.32%). In the subgroup analysis, a decline in mortality was also observed in patients requiring oxygen support but not mechanical ventilation (risk-adjusted mortality range = 5.98-11.68%; relative risk reduction = 22-60%; reference month of April 2020 = 15.06%). Further adjustments for medical procedure changes in the entire study population revealed a decrease in mortality in waves 2 and 3 (risk-adjusted mortality range = 2.66-4.05%; relative risk reduction = 24-50%).
A decline in in-hospital mortality was observed in waves 2 and 3 after adjusting for patient/hospital-level characteristics and medical treatments. The reasons for this decline warrant further research to improve the outcomes of hospitalized patients.
关于日本第 1、2 和 3 波 COVID-19 患者的临床流行病学和住院死亡率的时间趋势,信息有限。
使用国家索赔数据库分析了 COVID-19 患者入院、医疗程序和住院死亡率特征的时间趋势。纳入年龄≥18 岁且于 2020 年 1 月 1 日至 2021 年 2 月 28 日出院的患者。
对 51252 例患者进行的多水平逻辑回归分析显示,第 2 和第 3 波的死亡率下降(风险调整死亡率范围为 2.17-4.07%;相对风险降低 23-59%;参考月为 2020 年 4 月 5.32%)。在亚组分析中,需要氧疗但不需要机械通气的患者的死亡率也有所下降(风险调整死亡率范围为 5.98-11.68%;相对风险降低 22-60%;参考月为 2020 年 4 月 15.06%)。对整个研究人群的医疗程序变化进行进一步调整后,第 2 和第 3 波的死亡率下降(风险调整死亡率范围为 2.66-4.05%;相对风险降低 24-50%)。
在调整了患者/医院水平特征和治疗方法后,第 2 和第 3 波的住院死亡率下降。这种下降的原因需要进一步研究,以改善住院患者的预后。